Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
MLAB Price Action
Last 7 days
4.3%
Last 30 days
6.2%
Last 90 days
-16.0%
Trailing 12 Months
6.0%
MLAB RSI Chart
MLAB Valuation
MLAB Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
MLAB Fundamentals
MLAB Revenue
MLAB Earnings
MLAB Profitability
MLAB Investor Care
Revenue & Growth
Revenue Breakdown
As of: Dec 31, 2024
Product
| |||||||||||||||||||||||
| |||||||||||||||||||||||
| |||||||||||||||||||||||
| |||||||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2024 | 216.2M | 223.7M | 228.4M | 237.7M |
| 2023 | 219.1M | 219.3M | 213.7M | 212.9M |
| 2022 | 184.3M | 199.9M | 222.8M | 222.4M |
| 2021 | 133.9M | 138.9M | 142.9M | 163.4M |
| 2020 | 117.7M | 121.3M | 127.7M | 130.2M |
| 2019 | 103.1M | 104.3M | 105.0M | 109.9M |
| 2018 | 96.2M | 98.6M | 100.6M | 103.6M |
| 2017 | 93.7M | 95.2M | 93.8M | 93.6M |
| 2016 | 84.7M | 87.6M | 90.2M | 94.2M |
| 2015 | 71.3M | 73.1M | 76.3M | 78.4M |
| 2014 | 52.7M | 57.9M | 63.8M | 68.5M |
| 2013 | 46.4M | 47.1M | 48.1M | 49.8M |
| 2012 | 39.6M | 40.9M | 42.9M | 44.6M |
| 2011 | 34.2M | 35.7M | 37.4M | 39.0M |
| 2010 | 0 | 0 | 0 | 0 |
Get all data in R, Python etc through our Historical Stock Data APIs
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
| CEO | Mr. Gary M. Owens |
|---|---|
| WEBSITE | mesalabs.com |
| SECTOR | Technology |
| INDUSTRY | Scientific & Technical Instruments |
| EMPLOYEES | 698 |
